

AACR Special Conference on RNAs as Drivers, Targets, and Therapeutics in Cancer November 14-17, 2024 | Bellevue, WA



TITLES & ABSTRACT NUMBERS

Abstract Title	Abstract
HNRNPH1 regulates the alternative splicing of transcripts expressed by cancer-	Number A001
associated genes	AUUT
A therapeutically targetable positive feedback loop between long	B002
noncoding RNA-HLX-2-7, HLX, and MYC that promotes childhood cancer group 3	
medulloblastoma	
Multipronged SMAD Pathway Targeting by LiPBAE miR-590-3p NanomiRs Inhibits	B023
Recurrent Glioblastoma Growth and Prolongs Survival	
Targeting mRNA methyltransferase in RNA-dependent DNA repair in cancer therapy	A002,
Systematic loss-of-function screens identify pathway-specific functional circular RNAs	B003
Targeting Galectin-1 to enhance immuno-radiotherapy	A026
Snord67 promotes breast cancer metastasis through U6-mediated alternative splicing	A003
Ovarian cancer long intergenic noncoding RNA 1 is a potential therapeutic	B004
target in advanced ovarian cancer by promoting glycolytic pathway and hypoxic	
response	
RNA splicing alterations in the development of acquired MAPKi resistance in	A004
melanoma	
A robust NSCLC biomarker: miR-7-5p: in-silico validation and potential SPR-based	B005
probe for detection.	
Target validation and drug discovery efforts on exoribonuclease XRN1	A027
Preventing and treating HPV-related Cancer with mRNA Therapy Expressing A DC-	A028
targeting Antigen	
Rescuing expression of a tumor suppressor gene – restoring FH in Hereditary	B006
leiomyomatosis and renal cell carcinoma	-
APC mutations dysregulate alternative polyadenylation in cancer	A005
Unlocking antiviral immunity against endogenous retroviruses in skin squamous cell carcinomas	B007
Development of a syngeneic transplant rat model for the identification of	A006
an mRNA signature associated with metastatic hepatocellular carcinoma	
Exploring the Dual Roles of RNAs as Oncogenic Drivers and Therapeutic Targets in	B008
Cancer: A Cross-Sectional Study	
The RNA binding activity of the BRAF Kinase	B009
Systematical evaluation on alternative splicing in immune-related therapy targets	B010
reveals innate and acquired therapy resistance mechanisms in multiple myeloma.	
Characterization of miR-141 and miR-145 expression in cancer stem cells of metastatic	A007
prostate cancer patients	
RNA-based therapeutics to target the p53 pathway in cancer	B011
LncTransformer: Identifying novel prognostic long-noncoding RNA biomarkers	A020
for pancreatic cancer using deep learning	
HNRNPL-mediated mRNA stability underlies metastasis triggered by resistance to	B012
radiation therapy.	



AACR Special Conference on RNAs as Drivers, Targets, and Therapeutics in Cancer November 14-17, 2024 | Bellevue, WA



TITLES & ABSTRACT NUMBERS

<u>IIILLO & ADOTIAOT ITOTIDEITO</u>	
Identification of EYA2 as a promising biomarker for DICER1-related tumor predisposition	A008
To the tumor and beyond: Tales of a holistic miRNA delivery vehicle & https://www.action.com/action/	B024
RNA-Based Therapeutics to target the p53 pathway in high-grade serous ovarian	A025
cancer: TAp63-Regulated Oncogenic LncRNAs (TROLLs) as novel therapeutic targets in	
cancer	
Redox reprogramming by SOD1 knockdown: A novel liposomal siRNA strategy to	B025
overcome platinum resistance in ovarian cancer	
Investigation of a novel lncRNA, TROLL-9 , in breast cancer formation and	B013
progression	
Increasing the Sensitivity to sorafenib of Resistant Hepatocellular Carcinoma Cells	A009
with Bovine Lactoferrin through Ferroptosis	
Hypoxia-induced epigenetic changes coordinate transcription start site selection and	A010
translational control through remodeling of 5'UTRs	
mascRNA directs nutrient-insensitive activation of the LARS-mTOR pathway in breast	B014
cancer	
Second generation RNA Polymerase I inhibitor PMR-116 targets ribsomal	B015
RNA synthesis to potently treat a broad spectrum of malignancies	
Binding of the exon junction complex shapes the landscape of m6A in RNA - a possible	A011
source of m6A dysregulation in cancer	
Identification of small RNAs that function as multi-target therapeutics and as tools for	B026
novel target discovery in prostate cancer	
g3bp1-mediated stress granule formation drives melanoma initiation in	A012
zebrafish	5010
RNA demethylase ALKBH5 drives medulloblastoma growth and progression	B016
Discovery of cancer-specific small RNAs using a new unbiased analysis of cohort sequence data	B017
An Innovative cell-penetrating peptide-based RNAi Therapy to Overcome B-Raf/MEK	B027
Inhibitor Resistance in Melanoma	
miRNA-130a promotes Breast cancer progression by inhibiting multiple tumour	B018
suppressor genes as a Gene-TF-miRNA network	
Development and applications of a tool for accurate untargeted profiling of RNA	PR016
modifications	
A first-in-class EGFR-directed KRAS G12V selective inhibitor	B028
Molecular mechanisms of intron retention in Long Non-Coding RNAs	A013
RNA secondary structures mediate circular RNA stability and function	A023
Modulating the immunosuppressive pancreas tumor microenvironment through	A029
intratumoral delivery of cytokine-encoding mRNAs	
Beyond the LNP: Self-amplifying RNA with LION nanoformulation technology for	A030
development of safe and effective cancer therapeutics	
Androgen receptor-regulated lncRNA PRCAT71 promotes AR signaling through	B019
the interaction with RBPs in prostate cancer	



AACR Special Conference on RNAs as Drivers, Targets, and Therapeutics in Cancer November 14-17, 2024 | Bellevue, WA



TITLES & ABSTRACT NUMBERS

Identification, therapeutic potential, and regulatory networks of tumor suppressing miRNAs in angiosarcoma	A014
Decoding RNA metabolism by RNA-linked CRISPR screening in human cells	A021
The Ratio of Alternatively Spliced KRAS Isoforms Plays a Role in The Tumorigenesis of	B020
Colorectal Cancer	
CircRNA-derived neoantigen identification in cancer vaccine development	B001
DICER1 cancer predisposition tumor promotion mediated non-cell	B021
autonomously via neutrophils and NETosis.	
Characterizing invasiveness in CCCR cells: Role of miR-100, miR-125b and EVs	B022
PVT1 fusion on extrachromosomal DNA (ecDNA) increases oncogene RNA stability and	A015
cancer cell growth	
YBX1 is a negative regulator of post-transcriptional program associated with invasion	A016
and metastasis in cSCC	
IGF2BP1 is essential for ETO2/GLIS2 leukemogenesis via stabilization of primitive	A017
myeloid transcriptional programs	
Patho-DBiT: Spatially exploring RNA biology in archival formalin-fixed paraffin-	A022
embedded tissues	
Alternative Polyadenylation Regulates Pancreatic Cancer Fibroblast Metabolism	A018
Identification and Genomic Analysis of miRNA-mRNA Binding Site SNPs in Hepatitis C	A019
Virus-Associated Hepatocellular Carcinoma	
Assessing Mitondiral Priming in Leukemia Using BH3 Complex Specific Antibodies	A024
(PRIMABS): Prediciting Patient Response to Apoptosis Inducing Drugs	